Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • Breakthrough Discoveries
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      George J. Chang Image

      George J. Chang, MD, MS, MHCM, FACS, FASCO, FASCRS, FSSO

      Department of Colon & Rectal Surgery, Division of Surgery

      Meet George Chang, M.D.

      In the news

      Colon cancer cell

      Is colon cancer curable?

      George Chang, M.D.

      After overcoming coronavirus (COVID-19), surgeon donates plasma

      CGI of doctor in lab coat examining floating digital colon

      What is a total pelvic exenteration?

      Present Title & Affiliation

      Primary Appointment

      Associate Vice President, Clinical Growth and Site Integration, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Endowed Distinguished Chair Sue and Radcliff Killam Chair, The University of Texas MD Anderson Cancer Center, Houston, TX

      Professor, Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

      Professor (Joint appointment), Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX

      Research Interests

      Cancer treatment outcomes research.  Clinical epidemiology of cancer treatment outcomes.  Decision modeling for cancer treatment.

      Clinical trials in cancer therapy.

      Education & Training

      Degree-Granting Education

      2023Harvard T.H. Chan, School of Public Health, Boston, Massachusetts, US, MHCM in Master of Health Care Management
      2007The University of Texas Health Science Center at Houston Medical School, Houston, Texas, US, M.S. in Master of Science in Clinical Research
      1995University of California, Los Angeles, California, US, MD
      1991University of California, Berkeley, California, US, BA in Biochemistry

      Postgraduate Training

      2024-2024The Leading Teams Core Cohort, The University of Texas MD Anderson Cancer Center Leadership Institute, Houston, Texas
      2022-2022Emotional Intelligence Certificate, Vanderbilt University
      2020-2020Rice Advanced Management Program, Rice University School of Business, Houston, Texas
      2015-2015MD Anderson Faculty Leadership Academy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
      2013-2013Leadership Development for Physicians in Academic Health Centers, Harvard School of Public Health, Boston, Massachusetts
      2009-2009Measurement, Design, and Analysis Methods for Health Outcomes Research, Harvard School of Public Health, Boston, Massachusetts
      2003-2004Clinical Fellow, Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota
      2002-2003Chief Resident, Surgery, University of California, San Francisco, California
      1998-2001Post-doctoral Research Fellow, Surgery, University of California, San Francisco, California
      1996-2002Resident, Surgery, University of California, San Francisco, California
      1995-1996Intern, Surgery, University of California, San Francisco, California

      Licenses & Certifications

      2024Fellow of the American Society of Clinical Oncology
      2008Fellow of the American Society of Colon and Rectal Surgeons
      2008Fellow of the Society of Surgical Oncology
      2007Fellow of the American College of Surgeons
      2005American Board of Colon and Rectal Surgery
      2004American Board of Surgery

      Experience & Service

      Faculty Academic Appointments

      John E. and Dorothy J. Harris Professorship in Gastrointestinal Cancer Research, Surgical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2021

      Professor, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2020

      Associate Professor, Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2015

      Associate Professor, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2015

      Assistant Professor, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2004 - 2010

      Administrative Appointments/Responsibilities

      Department Chair ad interim, Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2025

      Associate Vice President, Regional Surgery Strategy, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2025

      Deputy Department Chair, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2020

      Activity Director, The Multidiscplianry Rectal Cancer Conference, Colon & Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2022

      Director, Advanced Colon and Rectal Surgical Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2020

      Chief, Section of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020

      Director of Clinical Operations, Minimally Invasive and New Technologies in Oncologic Surgery Program, The University of Texas MD Anderson Cancer Center, Houston, 2011 - 2019

      Associate Medical Director, Colorectal Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2017

      Other Professional Positions

      Advisory Board, Tempus, Chicago, IL, 2024

      Advisory Board, Agency for Healthcare Research and Quality, Rockville, MD, 2023 - 2024

      Advisory Board, Iota Biosciences, Alameda, CA, 2023 - 2024

      Panel, Ethicon Endo-Surgery, Inc, Cincinnati, OH, 2020

      Scientific Advisor, 11/Health, Irvine, CA, 2020

      Consultant, MORE Health, United States, 2018 - 2019

      Consultant, Ethicon Biosurgery Sentinel GI Advisory Board, Somerville, NJ, 2014 - 2015

      Consultant, Ethicon Endo-Surgery, Inc, Cincinnati, OH, 2013 - 2015

      Advisory Board, Synovis, St. Paul, MN, 2012

      Ad hoc advisory, Genomic Health, Redwood City, CA, 2011

      Ad hoc, Intuitive Surgical, Sunnyvale, CA, 2010 - 2011

      Ad hoc advisory, Agendia, Huntington Beach, CA, 2010

      Ad hoc advisory, Genzyme, Cambridge, MA, 2008 - 2009

      Ad hoc consultant, Covidien, Norwalk, CT, 2008 - 2009

      Consultantships, The University of Texas MD Anderson Orlando Teleconference GI Surgical Oncology, Houston, 2007 - 2010

      Ad hoc Consultant, Lifecell Corporation, Branchburg, NJ, 2007

      Extramural Institutional Committee Activities

      Member, National Comprehensive Cancer Network Colon | Rectal | Anal Cancers Panel, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Search Committee, Chief Nursing Executive, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Member, MD Anderson Physicians Network Board of Directors, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Chair, Editor in Chief Search Committee, Diseases of the Colon and Rectum, 2024 - 2026

      Member, Internal Advisory Board for the Shared Decision Making Core, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, Division of Surgery Executive Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, COVID-19 Core Leadership Team, Colorectal Service Line Lead, The University of Texas MD Anderson Cancer Center, 2020 - 2023

      Member, Cancer Survivorship Steering Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Search Committee, Department of Melanoma Chair, The University of Texas MD Anderson Cancer Center, 2018 - Present

      Member, Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2018 - 2022

      Member, Institutional Staging Workgroup, The University of Texas MD Anderson Cancer Center, 2017 - Present

      Member, Vice Provost Population Science Advisory Council, The University of Texas MD Anderson Cancer Center, 2017 - Present

      Member, Cancer Survivorship Research Advisory Workgroup, The University of Texas MD Anderson Cancer Center, 2017 - 2020

      Member, Clinical Effectiveness Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present

      Member, Search Committee, Department of Gastrointestinal Medical Oncology Chair, The University of Texas MD Anderson Cancer Center, 2014 - Present

      Surgical Oncology Representative, Division of Surgery Cancer Network Operations Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2022

      Member, Clinical Research Protocol Review Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present

      Member, eResearch Executive Steering Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present

      Member, Surgical Oncology Clinical Research Oversight Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2016

      Member, Perioperative Enterprise Laparoscopic Instrumentation Upgrade Task Force, The University of Texas MD Anderson Cancer Center, 2010 - 2011

      Member, Surgical Oncology Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2020

      Member, Clinical Affairs Sub Committee of the Faculty Senate, The University of Texas MD Anderson Cancer Center, 2009 - 2014

      Member, Volume Outcomes in Cancer Surgery Workgroup, The University of Texas MD Anderson Cancer Center, 2009 - 2011

      Member, Perioperative Enterprise Endoscopic Instrumentation Upgrade Taskforce, The University of Texas MD Anderson Cancer Center, 2009 - 2011

      Member, Colon and Rectal Cancer Treatment Guidelines Development Core Committee, The University of Texas MD Anderson Cancer Center, 2008 - Present

      Member, Perioperative Enterprise HD Video Upgrade Taskforce, The University of Texas MD Anderson Cancer Center, 2008 - 2010

      Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2007 - 2019

      Alternate Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2007 - 2008

      Executive Committee Member, Minimally Invasive and New Technologies in Oncology Surgery (MINTOS), The University of Texas MD Anderson Cancer Center, 2006 - Present

      ex officio, Medical Records Subcommittee, The University of Texas MD Anderson Cancer Center, 2006 - 2014

      Member, Commission on Cancer Site Visit Preparation Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2011

      Member, Cancer Liaison Physician, The University of Texas MD Anderson Cancer Center, 2005 - Present

      Member, 100K Lives Charter Team, The University of Texas MD Anderson Cancer Center, 2005 - Present

      Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2005 - 2008

      Member, Multidisciplinary Colorectal Cancer Strategic Planning Committee, The University of Texas MD Anderson Cancer Center, 2004 - Present

      Editorial Activities

      Member, Editorial Advisory Board, CANCER, 2026 - 2028

      Editorial Board, Journal of Clinical Oncology, 2026 - 2028

      Editor, Annals of Gastroenterological Surgery, 2020 - Present

      Member of Editorial Review Board, British Journal of Surgery, 2019 - 2024

      Member of Editorial Review Board, Annals of Gastroenterological Surgery, 2018 - Present

      Section Editor, Colorectal Oncology, Society of Surgical Oncology, 2015 - Present

      Member of Editorial Review Board, Frontiers in Oncology, 2014 - 2018

      Member of Editorial Review Board, Journal of Clinical Oncology, 2012 - 2019

      Associate Editor, Diseases of the Colon & Rectum, 2010 - Present

      Member of Editorial Review Board, Annals of Surgical Oncology, 2009 - Present

      Honors & Awards

      2026 - PresentBuie Award for Editorial Excellence, Disease of the Colon and Rectum
      2025 - PresentAmerica's Leading Doctors, Newsweek
      20232020 High Impact Article of Annals of Laparoscopic and Endoscopic Surgery, Annals of Laparoscopic and Endoscopic Surgery
      2023CAHPS top 1% performer, Physician Referral Service Annual Business Meeting and Recognition Awards
      20212021 National Top 10% Providers, Press Gainey
      20202020 National Top 1% Providers, Press Gainey
      2019Outstanding Teaching Award for Research, Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center
      2019SSO 2019 Best Clinical Research Paper (to mentee Zafar), Society of Surgical Oncology
      20192019 Star Performance, Diseases of the Colon and Rectum
      2018National Top 1% Providers, Press Gainey
      2015MD Anderson Cancer Center Presidential Clinical Technology Award for Faculty Excellence
      2014Most Outstanding Abstract Award, Academic Surgical Congress Annual Meeting
      2014Trainee Excellence Award (to mentee Christina Bailey), MD Anderson Alumni & Faculty Association
      2014Outstanding Teacher of the Year in Research Award, Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center
      2011Certificate of Merit, Radiological Society of North America
      2011Best Clinical Abstract Award, American Society of Colon and Rectal Surgeons
      2011Award for Outstanding Paper at the 2011 ASCRS Annual Meeting, Michigan Society of Colon and Rectal Surgeons
      2010 - 2023America's Top Surgeons, Consumers Research Council of America
      2010Trainee Research Poster Competition Finalist-to Mentee Tawnya Bowles, MD, UT MD Anderson Cancer Center
      2008 - 2011American Society of Clinical Oncology Career Development Award
      2007 - 2023Best Doctors in America
      2007Outstanding Manuscript Award (to mentee Lim), Society of Surgical Oncology
      2007Outstanding Abstract Award (to mentee Choi), ASCO GI Cancers Symposium
      2006Sharon K. Martin Award for Performance Improvement Excellence (Surgical Instrument Reduction)
      2006Department of Surgical Oncology Outstanding Teacher of the Year, UT M. D. Anderson Cancer Center
      2003Department of Surgery Azakie-Chessen Award for Compassion, University of California San Francisco School of Medicine
      2001Maurice Galante Award for Most Outstanding Resident Research, University of California San Francisco School of Medicine
      1999 - 2001A.P. Giannini Foundation Research Fellowship Award, Bank of America
      1999British Journal of Surgery Outstanding Resident Award
      1998Alpha Omega Alpha Distinguished Resident Teaching Award, University of California San Francisco School of Medicine
      1995Alpha Omega Alpha Delta Chapter, University of California Los Angeles School of Medicine
      1995William N. Valentine Medical Student Award for Highest Performance in Medicine
      1992 - 1993Josiah S. Brown Award for Excellence in Research, University of California Los Angeles School of Medicine
      1991 - 1995UCLA Medical Student Honors Thesis and Dean's Award
      1991Departmental Honors, University of California Berkeley Department of Biochemistry
      1990Phi Beta Kappa
      1987 - 1991National Merit Scholar, University of California Berkeley
      1987 - 1991Dean Honor Roll, UC Berkeley College of Letters and Sciences
      1987 - 1991Honors Research Thesis, UC Berkeley Department of Biochemistry
      1987 - 1991Golden Key National Honor Society, University of California Berkeley
      1985Summer Student Research Fellowship, California Academy of Science/City of Hope Beckman Research Institute

      Professional Memberships

      Korean Society of Coloproctology

      2025 - Present

      Agency for Healthcare Research and Quality

      2023 - Present

      Food and Drug Administration

      2022

      Ohio State University

      2022 - Present

      The Society of Asian Academic Surgeons

      2019 - Present

      American Surgical Association

      2019 - Present

      Data and Biospecimen Access Committee

      2017 - Present

      Society for Surgery of the Alimentary Tract

      2015 - Present

      Surgical Biology Club II

      2015 - Present

      Multidisciplinary International Rectal Cancer Society

      2012 - Present

      Alliance for Clinical Trials in Oncology Network

      2011 - Present

      OSTRiCh - Consortium for Optimizing Surgical Treatment of Rectal Cancer

      2011 - Present

      Society of University Surgeons

      2010 - Present

      American Board of Colon and Rectal Surgeons

      2010 - Present

      National Cancer Institute

      2009 - Present

      American College of Surgeons, Commission on Cancer

      2009 - Present

      Korean American Medical Association

      2009 - Present

      Clinical Robotic Surgery Association

      2009 - 2013

      Southwest Oncology Group (SWOG)

      2008 - Present

      American College of Surgeons Oncology Group

      2008 - 2011

      Surgical Outcomes Club

      2007 - Present

      Society of Medical Decision Making

      2006 - Present

      American Joint Committee on Cancer

      2006 - Present

      Society of Surgical Oncology

      2006 - Present

      American Society of Clinical Oncology

      2005 - Present

      Society of American Gastrointestinal and Endoscopic Surgeons

      2005 - Present

      Association for Academic Surgery

      2005 - Present

      Harris County Medical Association

      2004 - Present

      Texas Medical Association

      2004 - Present

      American Society of Colon and Rectal Surgeons

      2003 - Present

      Minnesota Medical Society

      2003 - 2004

      American College of Surgeons

      1997 - Present

      American Medical Association

      1991 - 2012

      California Medical Association

      1991 - 1997

      Grant & Contract Support

      Date: 2024 - 2029
      Title:An enhanced eHealth and Chat-bot enabled delivery model for clinical genetic services in community AYA cancer patients
      Funding Source:University of California
      Role:Co-PI
      ID:1R01CA284748-01A1
      Date: 2022 - 2024
      Title:PrehabPal: A digital tool to help frail elders prepare for cancer surgery
      Funding Source:Univ of California San Francisco
      Role:PI
      ID:FP00016259
      Date: 2021 - 2024
      Title:Magnetic nanoparticles for Precision Surgical Oncology and Radiotherapy
      Funding Source:Ferronova Pty Ltd
      Role:PI
      Date: 2021 - 2026
      Title:Effectiveness-Implementation trial of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer patients
      Funding Source:NIH/NCI
      Role:Co-I
      Date: 2021 - 2022
      Title:Enhancing Recovery Beyond Discharge (Enhanced Recovery Plus)
      Funding Source:American Soc of Colon and Rectal Surgeon
      Role:PI
      Date: 2019 - 2025
      Title:UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1
      Funding Source:UT MD Anderson Cancer Center Network Lead Academic Participating Site
      Role:Co-PI
      ID:5UG1CA233329-02
      Date: 2019 - 2025
      Title:NIH/NCI/Mayo. Alliance NCORP Research Base
      Funding Source:Mayo Clinic Rochester
      Role:PI
      ID:2UG1CA189823-06
      Date: 2019 - 2023
      Title:Older Mens Decision Making about Active Surveillance for Prostate Cancer
      Funding Source:American Cancer Society (ACS)
      Role:Co-Mentor
      ID:MRSG-18-225-01-CPPB
      Date: 2018 - 2025
      Title:Alliance NCORP Research Base - Cancer Care Delivery Research - OPTI-Surg Study
      Funding Source:Mayo Clinic Rochester
      Role:PI
      ID:5UG1CA1898823-05R
      Date: 2018 - Present
      Title:Alliance NCORP Research Base – Cancer Care Delivery Research – OPTI-Surg Study
      Funding Source:NIH/NCI/Mayo
      Role:PI
      ID:2UG1CA1898823-06
      Date: 2018 - 2023
      Title:Multicenter Cluster Randomized Trail of Preoperative Frailty Assessment and Intervention for Patients Undergoing Major Surgery
      Funding Source:Alliance NCORP Research Base
      Role:PI
      Date: 2018 - 2020
      Title:Organ Preservation with Active Surveillance after Chemoradiation in Rectal Cancer (OPTION), a Prospective trial
      Funding Source:The University of Texas MD Anderson Cancer Center
      Role:Principal Investigator-MDACC
      Date: 2016 - 2021
      Title:Large Pragmatic Trial. Patient Centered Outcomes Research Institute
      Funding Source:Comparison of Operative to Medical Endocrine Therapy (COMET) for low risk DCIS
      Role:Co-I
      Date: 2016 - 2018
      Title:Enhanced Accelerated Recovery following Minimally Invasive colorectal cancer surgery (RecoverMI), a Randomized Trial
      Funding Source:American Society of Colon and Rectal Surgeons
      Role:PI
      Date: 2016 - 2021
      Title:Arizona State University Exercise Intervention for Rectal Cancer Survivors
      Funding Source:NIH
      Role:Co-I
      Date: 2015 - 2019
      Title:Optimizing the Effectiveness of Routine Post-Treatment Surveillance in Prostate Cancer Survivors
      Funding Source:Alliance for Clinical Trials in Oncology Foundation through Patient Centered Outcomes Research Institute - PCORI
      Role:Principal Investigator-MDACC
      Date: 2014 - 2020
      Title:UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
      Funding Source:The University of Texas MD Anderson Cancer Center
      Role:Principal Investigator-MDACC
      ID:5U10CA180858
      Date: 2014 - 2020
      Title:Chang NCTN-LAP
      Funding Source:NIH/NCI
      Role:PI
      Date: 2014 - 2019
      Title:Alliance NCORP Reserach Base
      Funding Source:NCORP
      Role:Co-I
      ID:5UG1CA189823-04
      Date: 2014 - 2017
      Title:Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer
      Funding Source:ALLIANCE for Clinical Trials in Oncology Foundation through Patient Centered Outcomes Research Institute - PCORI
      Role:PI
      Date: 2014 - 2017
      Title:Improving the Effectiveness of Routine Surveillance Following Lung Cancer Resection
      Funding Source:ALLIANCE for Clinical Trials in Oncology Foundation through Patient Centered Outcomes Research Institute - PCORI
      Role:Principal Investigator-MDACC
      Date: 2014 - 2017
      Title:CCARE Colon Cancer Adjuvant Research and Experience. A Critical Decision Support Tool for Stage II Colon Cancer Patients and their Physicians
      Funding Source:Arizona State University through Patient Centered Outcomes Research Institute - PCORI
      Role:Principal Investigator-MDACC
      Date: 2013 - 2015
      Title:AMPK directs the balance between mutant Kras and PI3K signaling and defines molecular subsets in colorectal cancer
      Funding Source:MD Anderson Cancer Center Sister Institution Network Fund
      Role:Co-I
      Date: 2013 - 2014
      Title:American College of Surgeons Oncology Group/ NCI Community Clinical Oncology Program (CCOP) Research Base
      Funding Source:ACOSOG
      Role:Co-I
      ID:5U10CA149950-03
      Date: 2012 - 2022
      Title:A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
      Funding Source:ALLIANCE 7U10CA076001
      Role:PI
      ID:NCCTG N1048
      Date: 2012 - 2014
      Title:A Single Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Gastrointestinal Anastomosis Techniques
      Funding Source:Ethicon
      Role:PI
      ID:2012-0235
      Date: 2011 - 2021
      Title:A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients using ColoPrint
      Funding Source:Agendia
      Role:PI
      ID:CS2011-00035445LGA-01
      Date: 2011 - 2016
      Title:Alliance for Clinical Trials in Oncology Network Foundation
      Funding Source:ACTION Alliance /Brigham and Women's Hospital
      Role:Committee Co-Chair
      Date: 2011 - 2014
      Title:A phase III prospective randomized trial comparing laparoscopic-assisted resection versus open resection for rectal cancer
      Funding Source:American College of Surgeons Oncology Group/NCI
      Role:PI
      ID:7U10CA076001-16 ACOSOG-Z6051
      Date: 2010 - 2013
      Title:Statin Polyp Prevention Trial in Patients with Resected Colon Cancer (Phase III)
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:NSABP P-5
      Date: 2009 - 2014
      Title:Optimizing Treatment of Rectal Cancer Using a Markov Decision Model
      Funding Source:NIH/NCI
      Role:PI
      ID:5 K07 CA133187-05
      Date: 2008 - 2011
      Title:Development of a Markov Model for Optimized Treatment of Rectal Cancer
      Funding Source:American Society of Clinical Oncology (ASCO)
      Role:PI
      ID:Career Development Award
      Date: 2007 - Present
      Title:Development of a Markov Decision Model to Optimize Rectal Cancer Therapy
      Funding Source:American Cancer Society Career Development Award
      Role:PI
      Date: 2007 - Present
      Title:Leveraging Existing Data for Decision Support
      Funding Source:University of Texas Health Sciences Center, Center for Clinical and Translational Sciences Pilot Grant
      Role:Co-PI
      Date: 2006 - Present
      Title:Lymph Recovery as a Quality Indicator in Colon Cancer Surgery
      Funding Source:American Society of Colon and Rectal Surgery Research Foundation
      Role:PI
      Date: 1999 - 2001
      Title:Generation of Tolerance to Alloantigen in a Transplant Model Using Dendritic Cells, Costimulation Blockade and Immunomodulation
      Funding Source:Bank of America, A.P. Giannini Foundation
      Role:Research Fellow
      Date: 1998 - 1999
      Title:Generation of Tolerance to Alloantigen in a Transplant Model Using Dendritic Cells, Costimulation Blockade and Immunomodulation
      Funding Source:National Kidney Foundation
      Role:Research Fellow
      Date: 1993
      Title:Oxidation of Low-Density Lipoprotein by Nitric Oxide
      Funding Source:UCLA School of Medicine STTP Research Grant
      Role:Student Investigator
      Date: 1992
      Title:Oxidation of Low-Density Lipoprotein by nitric oxide
      Funding Source:UCLA School of Medicine STTP Research Grant
      Role:Student Investigator
      Title:AYA ACCESS Study: An enhanced eHealth and Chat-bot enabled delivery model for clinical genetic services in community AYA cancer patients
      Funding Source:NIH/R01
      Role:Co-I
      Title:General Surgery Resident Research Initiation Grant
      Funding Source:American Society of Colon & Rectal Surgeons
      Role:Co-Mentor
      Title:Exercise Intervention for Rectal Cancer Survivors
      Funding Source:University of Pennsylvania/NIH
      Role:Site PI
      ID:R01 CA226252-01
      Title:Human Centered Design for a Survivorship Social Network for Rectal Cancer
      Funding Source:UT Austin/MD Anderson Cancer Center
      Role:Co-PI

      Selected Publications

      Peer-Reviewed Articles

      1. Herb JN, Hu CY, Giordano SH, Chang GJ, Snyder RA. Association of social determinants of health diagnosis codes with overall survival in Medicare-insured patients with cancer. J Natl Cancer Inst, 2026. e-Pub 2026. PMID: 41849418.
      2. White MG, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Lutter-Berkova Z, Chang GJ, Futreal A, Wargo JA, Ajami NJ, Kopetz S, You YN. Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation With Response to Neoadjuvant Therapy. Ann Surg 278(4):538-548, 2023. e-Pub 2023. PMID: 37465976.
      3. Manisundaram N, DiBrito SR, Hu CY, Kim Y, Wick E, Palis B, Peacock O, Chang GJ. Reporting of Circumferential Resection Margin in Rectal Cancer Surgery. JAMA Surg 158(11):1195-1202, 2023. e-Pub 2023. PMID: 37728906.
      4. Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, Schrag D. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol 41(21):JCO2300903, 2023. e-Pub 2023. PMID: 37270691.
      5. Peacock O, Manisundaram N, Kim Y, Konishi T, Stanietzky N, Vikram R, Bednarski BK, You YN, Chang GJ. Therapeutic lateral pelvic lymph node dissection in rectal cancer: when to dissect? Size is not everything. Br J Surg 110(8):985-986, 2023. e-Pub 2023. PMID: 37150892.
      6. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med 389(4):322-334, 2023. e-Pub 2023. PMID: 37272534.
      7. Leitao MM, Kreaden US, Laudone V, Park BJ, Pappou EP, Davis JW, Rice DC, Chang GJ, Rossi EC, Hebert AE, Slee A, Gonen M. The RECOURSE Study: Long-term Oncologic Outcomes Associated with Robotically Assisted Minimally Invasive Procedures for Endometrial, Cervical, cOlorectal, lUng, or pRoState cancEr: a Systematic Review and meta-analysis. Ann Surg 277(3):387-396, 2022. e-Pub 2022. PMID: 36073772.
      8. Schumacher JR, Neuman HB, Yu M, Vanness DJ, Si Y, Burnside ES, Ruddy KJ, Partridge AH, Schrag D, Edge SB, Zhang Y, Jacobs EA, Havlena J, Francescatti AB, Winchester DP, McKellar DP, Spears PA, Kozower BD, Chang GJ, Greenberg CC, Working Group AACBCS. Surveillance imaging vs symptomatic recurrence detection and survival in stage II-III breast cancer (AFT-01). J Natl Cancer Inst 114(10):1371-1379, 2022. e-Pub 2022. PMID: 35913454.
      9. Peacock O, Vilar E, Trueba MG, Thirumurthi S, Chang GJ, You YN. Clinically Significant Metachronous Colorectal Pathology Detected Among Young-Onset Colorectal Cancer Survivors: Implications for Post-Resection Surveillance Guidelines. Gastroenterology, 2022. e-Pub 2022. PMID: 35987446.
      10. Snyder RA, Hu CY, DiBrito SR, Chang GJ. Association of Medicaid expansion with racial disparities in cancer stage at presentation. Cancer 128(18):3340-3351, 2022. e-Pub 2022. PMID: 35818763.
      11. Peacock O, Manisundaram N, Dibrito SR, Kim Y, Hu CY, Bednarski BK, Konishi T, Stanietzky N, Vikram R, Kaur H, Taggart MW, Dasari A, Holliday EB, You YN, Chang GJ. Magnetic Resonance Imaging Directed Surgical Decision Making for Lateral Pelvic Lymph Node Dissection in Rectal Cancer after Total Neoadjuvant Therapy (TNT). Ann Surg 276(4):654-664, 2022. e-Pub 2022. PMID: 35837891.
      12. De B, Corrigan KL, Rooney MK, Ludmir EB, Das P, Smith GL, Taniguchi CM, Minsky BD, Koay EJ, Koong A, Morris VK, Messick CA, You YN, Chang GJ, Westney OL, Nogueras Gonzalez GM, Holliday EB. Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys 114(1):78-88, 2022. e-Pub 2022. PMID: 35589011.
      13. Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, Taggart M, Salem U, Overman M, Kopetz S, Chang GJ. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg 109(6):489-492, 2022. e-Pub 2022. PMID: 35576377.
      14. Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, Taggart M, Salem U, Overman M, Kopetz S, Chang GJ. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg, 2022. e-Pub 2022. PMID: 35373260.
      15. Tilburt JC, Zahrieh D, Pacyna JE, Petereit DG, Kaur JS, Rapkin BD, Grubb RL, Chang GJ, Morris MJ, Kovac EZ, Babaian KN, Sloan JA, Basch EM, Peil ES, Dueck AC, Novotny PJ, Paskett ED, Buckner JC, Joyce DD, Montori VM, Frosch DL, Volk RJ, Kim SP. Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). Cancer 128(6):1242-1251, 2021. e-Pub 2021. PMID: 34890060.
      16. Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Andre T. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. J Natl Cancer Inst 113(2):208-211, 2021. e-Pub 2021. PMID: 32294214.
      17. Kothari AN, Trans AT, Caudle AS, Clemens MW, Katz MHG, Woodman SE, Chang GJ. Universal preoperative SARS-CoV-2 testing can facilitate safe surgical treatment during local COVID-19 surges. Br J Surg 108(1):e24-e26, 2021. e-Pub 2021. PMID: 33640925.
      18. Healy MA, Peacock O, Hu CY, Bednarski BK, Tillman MM, Messick C, Kaur H, Chang GJ. High Rate of Positive Circumferential Resection Margin in Colon Cancer: A National Appraisal and Call for Action. Ann Surg, 2020. e-Pub 2020. PMID: 33630474.
      19. Snyder RA, Hu CY, Zafar SN, Francescatti A, Chang GJ. Racial Disparities in Recurrence and Overall Survival in Patients with Locoregional Colorectal Cancer. J Natl Cancer Inst 113(6):770-777, 2020. e-Pub 2020. PMID: 33231683.
      20. An Y, Bellato V, Konishi T, Pellino G, Sensi B, Siragusa L, Franceschilli M, Sica GS, Group SC. Surgeons' fear of getting infected by COVID19: A global survey. Br J Surg 107(11):e543-e544, 2020. e-Pub 2020. PMID: 32808678.
      21. Collaborative P. The global cost of pelvic exenteration: in-hospital perioperative costs. Br J Surg 107(11):e470-e471, 2020. e-Pub 2020. PMID: 33460051.
      22. Peacock O, Limvorapitak T, Hu CY, Bednarski BK, Tillman MM, Kaur H, Taggart MW, Dasari A, Holliday EB, You YN, Chang GJ. Robotic rectal cancer surgery: comparative study of the impact of obesity on early outcomes. Br J Surg 107(12):1552-1557, 2020. e-Pub 2020. PMID: 32996597.
      23. Collaborative P. The impact of the COVID-19 pandemic on the Management of Locally Advanced Primary/Recurrent Rectal Cancer. Br J Surg 107(11):e547-e548, 2020. e-Pub 2020. PMID: 32779191.
      24. Bellato V, Konishi T, Pellino G, An Y, Piciocchi A, Sensi B, Siragusa L, Khanna K, Pirozzi BM, Franceschilli M, Campanelli M, Efetov S, Sica GS, Group SC. Impact of asymptomatic COVID-19 patients in global surgical practice during the COVID-19 pandemic. Br J Surg 107(10):e364-e365, 2020. e-Pub 2020. PMID: 32767367.
      25. Chang GJ, You YNY, Russell CA, Tierno MB, Turner M, Bennett JP, Lau A, Hochster HS. Young-Onset Colon Cancer and Recurrence Risk By Gene Expression. J Natl Cancer Inst 112(11):1170-1173, 2020. e-Pub 2020. PMID: 32040172.
      26. Massarweh NN, Chang GJ. Translating Research Findings Into Practice-The Unfulfilled and Unclear Mission of Observational Data. JAMA Surg 154(2):103-104, 2019. e-Pub 2019. PMID: 30422255.
      27. Bednarski BK, Nickerson TP, You YN, Messick CA, Speer B, Gottumukkala V, Manandhar M, Weldon M, Dean EM, Qiao W, Wang X, Chang GJ. Randomized clinical trial of accelerated enhanced recovery after minimally invasive colorectal cancer surgery (RecoverMI trial). Br J Surg 106(10):1311-1318, 2019. e-Pub 2019. PMID: 31216065.
      28. Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, Schrag D. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol 36(31):JCO2018788620, 2018. e-Pub 2018. PMID: 30204536.
      29. McMurry TL, Stukenborg GJ, Kessler LG, Colditz GA, Wong ML, Francescatti AB, Jones DR, Schumacher JR, Greenberg CC, Chang GJ, Winchester DP, McKellar DP, Kozower BD. More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study. Ann Surg 268(4):632-639, 2018. e-Pub 2018. PMID: 30004919.
      30. Kolarich A, George TJ, Hughes SJ, Delitto D, Allegra CJ, Hall WA, Chang GJ, Tan SA, Shaw CM, Iqbal A. Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease. Cancer 124(17):3510-3519, 2018. e-Pub 2018. PMID: 29984547.
      31. Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, Van Loon K, You YN, Kozower BD, Greenberg CC, Schrag D, Venook A, McKellar D, Winchester DP, Chang GJ, Working Group AFCTIONCSO. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer. JAMA 319(20):2104-2115, 2018. e-Pub 2018. PMID: 29800181.
      32. Delitto D, George TJ, Loftus TJ, Qiu P, Chang GJ, Allegra CJ, Hall WA, Hughes SJ, Tan SA, Shaw CM, Iqbal A. Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. J Natl Cancer Inst 110(5):460-466, 2018. e-Pub 2018. PMID: 29165692.
      33. Mason MC, Chang GJ, Petersen LA, Sada YH, Tran Cao HS, Chai C, Berger DH, Massarweh NN. National Quality Forum Colon Cancer Quality Metric Performance: How Are Hospitals Measuring Up?. Ann Surg 266(6):1013-1020, 2017. e-Pub 2017. PMID: 27617852.
      34. Carlos RC, Sicks JD, Chang GJ, Lyss AP, Stewart TL, Sung L, Weaver KE. Capacity for Cancer Care Delivery Research in National Cancer Institute Community Oncology Research Program Community Practices: Availability of Radiology and Primary Care Research Partners. J Am Coll Radiol 14(12):1530-1537, 2017. e-Pub 2017. PMID: 29055605.
      35. Cata JP, Guerra CE, Chang GJ, Gottumukkala V, Joshi GP. Non-steroidal anti-inflammatory drugs in the oncological surgical population: beneficial or harmful? A systematic review of the literature. Br J Anaesth 119(4):750-764, 2017. e-Pub 2017. PMID: 29121285.
      36. Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol 35(23):JCO2016721464, 2017. e-Pub 2017. PMID: 28657814.
      37. Alawadi Z, Phatak UR, Hu CY, Bailey CE, You YN, Kao LS, Massarweh NN, Feig BW, Rodriguez-Bigas MA, Skibber JM, Chang GJ. Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer. Cancer 123(7):1124-1133, 2017. e-Pub 2017. PMID: 27479827.
      38. Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P. Hyperfractioned Accelerated Reirradiation for Rectal Cancer. An Analysis of Outcomes and Toxicity. Radiother Oncol 122(1):146-151, 2017. e-Pub 2017. PMID: 28057329.
      39. de Rosa N, Rodriguez-Bigas MA, Chang GJ, Veerapong J, Borras E, Krishnan S, Bednarski B, Messick CA, Skibber JM, Feig BW, Lynch PM, Vilar E, You YN. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol 34(25):3039-3046, 2016. e-Pub 2016. PMID: 27432916.
      40. Lynch PM, Morris JS, Wen S, Advani SM, Ross W, Chang GJ, Rodriguez-Bigas M, Raju GS, Ricciardiello L, Iwama T, Rossi BM, Pellise M, Stoffel E, Wise PE, Bertario L, Saunders B, Burt R, Belluzzi A, Ahnen D, Matsubara N, Bülow S, Jespersen N, Clark SK, Erdman SH, Markowitz AJ, Bernstein I, De Haas N, Syngal S, Moeslein G. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 84(1):115-125.e4, 2016. e-Pub 2016. PMID: 26769407.
      41. You YN, Skibber JM, Hu CY, Crane CH, Das P, Kopetz ES, Eng C, Feig BW, Rodriguez-Bigas MA, Chang GJ. Impact of multimodal therapy in locally recurrent rectal cancer. Br J Surg 103(6):753-762, 2016. e-Pub 2016. PMID: 26933792.
      42. Rickles AS, Dietz DW, Chang GJ, Wexner SD, Berho ME, Remzi FH, Greene FL, Fleshman JW, Abbas MA, Peters W, Noyes K, Monson JR, Fleming FJ, Cancer (OSTRiCh) CFOTTOR. High Rate of Positive Circumferential Resection Margins Following Rectal Cancer Surgery: A Call to Action. Ann Surg 262(6):891-8, 2015. e-Pub 2015. PMID: 26473651.
      43. Patel S, Chang GJ. Primary Tumor Resection in Metastatic Colorectal Cancer: Please Pass the Salt. JAMA Oncol 1(9):1213-4, 2015. e-Pub 2015. PMID: 26378904.
      44. Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR, Maun D, Chang GJ, Herline A, Fichera A, Mutch M, Wexner S, Whiteford M, Marks J, Birnbaum E, Margolin D, Larson D, Marcello P, Posner M, Read T, Monson J, Wren SM, Pisters PW, Nelson H. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA 314(13):1346-55, 2015. e-Pub 2015. PMID: 26441179.
      45. Massarweh NN, Haynes AB, Chiang YJ, Chang GJ, You YN, Feig BW, Cormier JN. Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough?. Ann Surg 262(2):312-20, 2015. e-Pub 2015. PMID: 25185467.
      46. Hu CY, Bailey CE, Chang GJ. Less Surgery, Improved Survival From Stage IV Colorectal Cancer?-Reply. JAMA Surg 150(8):819-20, 2015. e-Pub 2015. PMID: 26107989.
      47. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
      48. Zheng Z, Jemal A, Lin CC, Hu CY, Chang GJ. Comparative Effectiveness of Laparoscopy vs. Open Colectomy Among Non-metastatic Colon Cancer Patients: An Analysis Using the National Cancer Data Base. J Natl Cancer Inst 107(3), 2015. e-Pub 2015. PMID: 25663688.
      49. Hu CY, Bailey CE, You YN, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ. Time Trend Analysis of Primary Tumor Resection for Stage IV Colorectal Cancer: Less Surgery, Improved Survival. JAMA Surg 150(3):245-51, 2015. e-Pub 2015. PMID: 25588105.
      50. Bailey CE, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010. JAMA Surg 150(1):1-6, 2015. e-Pub 2015. PMID: 25372703.
      51. Kneuertz PJ, GJ C, Hu CY, Rodriguez-Bigas MA, Eng C, Vilar E, Skibber JM, Feig BW, Cormier JN, You YN. Overtreatment of Young Adults With Colon Cancer: More Intense Treatments With Unmatched Survival Gains. JAMA Surg 150(5):402-9, 2015. e-Pub 2015. PMID: 25806815.
      52. Dineen S, Lynch PM, Rodriguez-Bigas MA, Bannon S, Taggart M, Reeves C, Modaro C, Overman M, Chang GJ, Skibber JM, You YN. A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. J Natl Compr Canc Netw 13(7):865-72, 2015. e-Pub 2015. PMID: 26150580.
      53. Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer 120(8):1162-70, 2014. e-Pub 2014. PMID: 24474245.
      54. Massarweh NN, Chiang YJ, Xing Y, Chang GJ, Haynes AB, You YN, Feig BW, Cormier JN. Association Between Travel Distance and Metastatic Disease at Diagnosis Among Patients With Colon Cancer. J Clin Oncol 32(9):942-8, 2014. e-Pub 2014. PMID: 24516014.
      55. Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys 88(2):301-5, 2014. e-Pub 2014. PMID: 24315563.
      56. Monson JR, Probst CP, Wexner SD, Remzi FH, Fleshman JW, Garcia-Aguilar J, Chang GJ, Dietz DW, Cancer (OSTRiCh) CFOTTOR. Failure of evidence-based cancer care in the United States: the association between rectal cancer treatment, cancer center volume, and geography. Ann Surg 260(4):625-31; discussion 631-2, 2014. e-Pub 2014. PMID: 25203879.
      57. Massarweh NN, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Cormier JN, Feig BW, Chang GJ. Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery. J Clin Oncol 32(27):2967-74, 2014. e-Pub 2014. PMID: 25092785.
      58. Eng C, Chang GJ, You YN, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane CH. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer 119(21):3769-75, 2013. e-Pub 2013. PMID: 24037775.
      59. Russell MC, You YN, Hu CY, Cormier JN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Nelson H, Chang GJ. A Novel Risk-Adjusted Nomogram for Rectal Cancer Surgery Outcomes. JAMA Surg 148(8):1-9, 2013. e-Pub 2013. PMID: 23803722.
      60. Collaborative BT. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg 100(8):E1-E33, 2013. e-Pub 2013. PMID: 23754654.
      61. Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, Mansfield P, Chang GJ. Improving the AJCC/TNM Staging for Adenocarcinomas of the Appendix: The Prognostic Impact of Histological Grade. Ann Surg 257(6):1072-8, 2013. e-Pub 2013. PMID: 23001080.
      62. Hu CY, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer 119(10):1900-7, 2013. e-Pub 2013. PMID: 23408226.
      63. Yi M, Xu J, Liu P, Chang GJ, Du XL, Hu CY, Song Y, He J, Ren Y, Wei Y, Yang J, Hunt KK, Li X. Comparative analysis of lifestyle factors, screening test use, and clinicopathologic features in association with survival among Asian Americans with colorectal cancer. Br J Cancer 108(7):1508-14, 2013. e-Pub 2013. PMID: 23470470.
      64. Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, Hu CY, Feig BW, You YN, Cormier JN. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 119(8):1593-601, 2013. e-Pub 2013. PMID: 23280510.
      65. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 119(24):4231-41, 2013. e-Pub 2013. PMID: 24089344.
      66. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 30(15):1770-6, 2012. e-Pub 2012. PMID: 22493423.
      67. Chagpar R, Xing Y, Chiang YJ, Feig BW, Chang GJ, You YN, Cormier JN. Adherence to Stage-Specific Treatment Guidelines for Patients With Colon Cancer. J Clin Oncol 30(9):972-9, 2012. e-Pub 2012. PMID: 22355049.
      68. Das P, Delclos ME, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Bedi M, Krishnan S, Crane CH. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys 77(1):60-5, 2010. e-Pub 2010. PMID: 19695792.
      69. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76(3):824-30, 2010. e-Pub 2010. PMID: 19464823.
      70. Smith KD, Tan D, Das P, Chang GJ, Kattepogu K, Feig BW, Skibber JM, Rodriguez-Bigas MA. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 251(2):261-4, 2010. e-Pub 2010. PMID: 19864936.
      71. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102(6):401-9, 2010. e-Pub 2010. PMID: 20185801.
      72. Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA. Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol 27(35):5938-43, 2009. e-Pub 2009. PMID: 19805670.
      73. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 2009. e-Pub 2009. PMID: 19470929.
      74. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P. Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys 74(3):818-23, 2009. e-Pub 2009. PMID: 19147305.
      75. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5254-60, 2008. e-Pub 2008. PMID: 18854565.

      Review Articles

      1. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. e-Pub 2022. PMID: 35608860.
      2. Bhutiani N, Peacock O, Chang GJ. A practical framework for the targeted use of total neoadjuvant therapy for rectal cancer. Cancer 128(11):2064-2072, 2022. e-Pub 2022. PMID: 35377951.
      3. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. Pre-Existing Melanoma and Hematological Malignancies, Prognosis and Timing to Solid Organ Transplantation: A Consensus Expert Opinion Statement. Am J Transplant 21(2):475-483, 2020. e-Pub 2020. PMID: 32976703.
      4. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qauod T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. Pre-Transplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement. Am J Transplant 21(2):460-474, 2020. e-Pub 2020. PMID: 32969590.

      Professional Educational Materials

      1. Benson AB, Venook AP, Adam M, Chang GJ, Chen Y, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology, 2024.
      2. Chang GJ. The ASCRS Manual of Colon and Rectal Surgery: Rectal Cancer: Watch and Wait. Springer Nature, 2019.
      3. Chang G. Audio-Digest General Surgery Board Review: Multidisciplinary Treatment of Rectal Cancer. Audio-Digest Foundation, 2013.
      4. Chang GJ. Update on multidisciplinary therapy for locally advanced rectal cancer, 2012.
      5. Chang GJ. Molecular Profiling for Colon Cancer: PRO. American Society of Clinical Oncology Gastrointestinal Symposium Educational book, 2012.
      6. Chang, GJ. Update on multidisciplinary therapy for locally advanced rectal cancer, 2010.
      7. Chang GJ. Rectal Cancer Treatment Guidelines - Treatment Algorythm. MD Anderson Cancer Center, 2009.
      8. Chang GJ. Colon Cancer Treatment Guidelines - Treatment Algorythm. MD Anderson Cancer Center, 2009.
      9. Feig BW, Chang GJ. Sentinel Node Assessment in Colorectal Cancer: Potential Advantages and Obstacles." American Society of Clinical Oncology Educational Book, 2007.
      10. Chang GJ. Issues in the treatment of colorectal cancer: Not for surgeons only. Highlights of the American Society of Colon and Rectal Surgeons (ASCRS) 2005 Annual Meeting, 2005.

      Editorials

      1. Guraieb-Trueba M, Chang GJ. Transanal vs Laparoscopic TME--all that Glitters is not Gold. Ann Surg 277(1):7-8, 2022. PMID: 35916131.
      2. Snyder RA, He J, Le-Rademacher J, Ou FS, Dodge AB, Zemla TJ, Paskett ED, Chang GJ, Innocenti F, Blanke C, Lenz HJ, Polite BN, Venook AP. Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). Cancer 127(20):3801-3808, 2021. PMID: 34374082.
      3. Chang GJ. Primary Tumor Resection in Colorectal Cancer With Synchronous Unresectable Metastasis: Time to End the Debate?. J Clin Oncol 39(10):JCO2100057, 2021. PMID: 33591837.
      4. Snyder RA, Chang GJ. Insurance Status as a Surrogate for Social Determinants of Health in Cancer Clinical Trials. JAMA Netw Open 3(4):e203890, 2020. PMID: 32352526.
      5. Sammour T, Malakorn S, Bednarski BK, Kaur H, Shin US, Messick C, You YN, Chang GJ. Oncological Outcomes After Robotic Protectomy for Rectal Cancer: Analysis of a Prospective Database. Ann Surg 267(3):521-526, 2018. PMID: 27997470.
      6. Chang GJ, Gonen M. Prognostic and Predictive Ability of Tumor Sidedness: Another Vexing Difference Between Localized and Advanced Colon Cancer. JAMA Oncol 3(10):1314-1315, 2017. PMID: 28594984.
      7. Sandhu L, Chang GJ. Which Surgical Approach Is Best for Management of Rectal Cancer?: Does the End Point Tell How It Ends?. JAMA Surg 152(4):e165659, 2017. PMID: 28196188.
      8. Chang GJ, Kopetz S. Coordination of Care in Colon Cancer. Cancer 121(18):3201-3202, 2015. PMID: 26043269.
      9. Chang GJ. Challenge of Primary Tumor Management in Patients with Stage IV Colorectal Cancer. J Clin Oncol 30(26):3165-6, 2012. PMID: 22869881.

      Abstracts

      1. White M, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Berkova Z, Nguyen ST, Chang GJ, Wargo JA, Ajami NJ, Kopetz S, Y Nancy You. Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy, 2024. e-Pub 2024.
      2. Uppal A, Bhutiani N, YC Shen JP, Alfaro K, Kell RJ, Yousef MM, Yousef AM, Konishi T, Holliday E, Van K Morris II, Dasari A, Willis J, Newhook TE, Bednarski BK, Y Nancy You, Peacock O, Messick C, Das P, Chang GJ, Kopetz S. Association of pathologic nodal status with minimal residual disease after neoadjuvant treatment and resection of locally advanced rectal cancer, 2024. e-Pub 2024.
      3. Finlayson E, Gunn H, Barber A, Lowenstein LM, Dohan DP, Broering JM, Dockter T, Tan AD, Dueck AC, Bailey L, Chow SL, Wills R, Jatoi Am Lee EK, Delacoix SE, Gills J, Mulligan C, Hayseen T, Chang GJ. Geriatric pre-surgical optimization in the NCORP (Alliance), 2023. e-Pub 2023.
      4. Childers C, Manisundaram N, Hu CY, Tran Cao HS, Chang GJ. Association of the Robotic Approach With Delays in Surgery For Colon Cancer, 2023. e-Pub 2023.
      5. Childers C, Manisundaram, Hu CY, Chang GJ. Does Submitting A Modifier 22 Actually Work?, 2023. e-Pub 2023.
      6. Manisundaram N, Hu CY, Uppal A, Peacock O, Bednarski BK, Konishi T, White M, You YN, Messick C, Tillman MM, Skibber JM, Das P, Smith GL, Holliday E, Dasari A, Johnson B, Morris VK, Chang GJ. Is There an Increase in Elective Utilization of Non-Operative Management for Rectal Cancer?, 2023. e-Pub 2023.
      7. Chang GJ, Gunn H, Barger A, Lowenstein LM, Dohan DP, Broering JM, Dockter T, Tan AD, Dueck AC, Bailey L, Chow SL, Cleary RK, Mesleh M, Woodall C, Solfelt ML, Finlayson E. Surgical care and outcomes in older patients with cancer through implementation of a pre-surgical toolkit (OPTI-Surg): Interim results of a phase III cluster randomized trial (Alliance A231601CD), 2023. e-Pub 2023.
      8. Fox DA, Konishi T, Kaur H, You YN, Raghav KP, Ge PS, Messick CA, Johnson B, Morris VK, Thomas JV, Shah P, Bednarski BK, Kopetz S, Chang GJ, Ludford K, Hibie V, Overman MJ, Bhamidipati D. Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response, 2023. e-Pub 2023.
      9. Dasari A, Bent AH, Alfaro-Munoz K, Huey RW, Johnson B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian CM, Raghav KPS, Shen J, Willis J, Newhook TE, Uppal A, You YN, Konishi T Chang GJ, Kopetz S, Wolff RA. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program, 2023. e-Pub 2023.
      10. Corrigan KL, Holliday E, Guraieb-Trueba M, Peacock O, Skibber JM, Bednarski BK, Messick C, Tillman MM, Johnson B, Smith GL, Nguyen ST, Kundu S, Reinhardt A, Chang GJ Das P, You YN. A prospective evaluation of pelvic radiation vs. no radiation among patients with young-onset rectal cancer: Impact on patient-reported outcomes, 2023. e-Pub 2023.
      11. Manisundaram N, Snyder RA, Hu CY, DiBrito SR, Chang GJ. Racial Disparities in Cancer Mortality in Patients with Gastrointestinal Malignancies Following Medicaid Expansion, 2023. e-Pub 2023.
      12. Janak A, Peacock O, White M, Guraieb-Trueba M, Nguyen ST, Alshenaifi J, Kopetz S, Johnson B, Smith GL, Chang GJ, You YN. Internet-based assessment tools for predicting colorectal cancer risk: How do they communicate individualized risk to the young adult?, 2023. e-Pub 2023.
      13. Uppal A, White M, Chang GJ, Zeineddine FA, Zeineddine MA, Abdelrahman MG, Scally C, Fournier K, Newhook TE, You YN, Willis J, Kopetz S, Shen JP. Tumor Mutations Associated with Outcomes in Colorectal Peritoneal Metastases, 2023. e-Pub 2023.
      14. Janak A, Peacock O, White M, Guraieb-Trueba M, Nguyen ST, Alshenaifi J, Kopetz S, Johnson B, Smith GL, Chang GJ, You YN. Internet-based assessment tools for predicting colorectal cancer risk: How do they communicate individualized risk to the young adult?, 2023. e-Pub 2023.
      15. Bhutiani N, Hu CY, Palis BE, Cotler J, Shi Q, Goldberg RM, Washington MK, Nelson H, Steele S, Chang GJ. Lack of hierarchical survival prognosis in AJCC staging for colon cancer: Implications for future summary stage classification, 2023. e-Pub 2023.
      16. Agnes A, Peacock O, Manisundaram N, Konishi T, Bednarski B, Taggart M, Vikram R, Stanietzky N, You YN, Poster Presentaion CG. Evaluation of the learning-curve for robotic lateral pelvic lymph node dissection (LPLND) for the treatment of rectal cencer in a Western institution, 2022. e-Pub 2022.
      17. Martin AN, Tzeng CW, Arvide EM Skibber JM, GJ &, You YN, Bednarski BK, Dewhurst WL, Cristo JV, Chun YS, Tran Cao HS, Vauthey JN, Newhook TE. Cumulative operative time and postoperative complication risk in synchronous resection of colorectal liver metastases and primary tumors, 2022. e-Pub 2022.
      18. Taku N, You YN, Ludmir EB, Smith GL, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Koong AC, Minsky BD, Holliday EB, Joay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Overman MJ, Kopez S, Raghav K, Das P. Clinical Outcomes Following Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer: A Single Institution Experience(suppl 15; abstr e15601), 2021. e-Pub 2021.
      19. Conti RM, McCue S, Dockter T, Rapkin BD, Dusetzina S, Bennett AV, Garcia G, Johnson ME, Martin SA, Chang GJ, Richardson PG, Behrens RJ, Weiss ES. Assessing Financial Difficulty In Patients With Multiple Myeloma: Preliminary Results of ALLIANCE A231602CD(suppl 15; abstr 8031), 2021. e-Pub 2021.
      20. You YN, Rodriguez-Bigas MA, Chang GJ, Bednarski BK, Skibber JM, Mork ME, Moskowitz JB, Nguyen ST, Thirumurthi S, Lynch PM, Kopetz S, Vilar Sanchez E. Are Current Family-history Based Colorectal Cancer Screening Guidelines Adequate For Early Detection And Potential Prevention Of Young-Onset Cases?(suppl 15; abstr 3549), 2021. e-Pub 2021.
      21. Swords DS, Tran Cao HS, Bednarski BK, Vauthey JN, Chang GJ, You YN. Treatment Disparities Partially Mediate Diminished Survival in Disadvantaged Black and White Patients with Stage IV Colorectal Cancer (CRC), 2021. e-Pub 2021.
      22. Zafar S, Hu C, Helmink B, Scally CP, Bednarski BK, Fournier KF, Chang GJ. Peritoneal Recurrence after Resection for Stage 1-3 Colorectal Cancer-A Popular Analysis, 2020. e-Pub 2020.
      23. Peacock O, Yun Y, Thirmurthi S, Nguyen S, Lim P, Rodriguez-bigas MA, Bednarski BK, Messick CA, Skibber JM, Chang GJ, Vilar E, You YN. Metachronous colorectal pathology among survivors of young-onset colorectal cancer: Implications for postresection colonoscopic surveillance, 2020. e-Pub 2020.
      24. Tilburt JC, Pacyna JE, Petereit DG, Kaur JS, Rapkin BD, Grubb R, Chang GJ, Morris MJ, Kovac E, Sloa JA, Basch EM, Storrick EM, Zahrieh D, Dueck AC, Paskett ED, Buckner JC, Montori V, Frosch DL, Volk RJ, Kim SP. Decision aids for localized prostate cancer: Initial outcomes from NCI Community Oncology Research Program Alliance Research Base Cancer Care Delivery Research (CCDR) Protocol - A191402CD - A Cluster-Randomized Trial, 2020. e-Pub 2020.
      25. Schrag D, Shi Q, Gollub MJ, Saltz LB, Chang GJ, Basch EM, Kolevska T, Gordon VL, Venook AP, O'Reilly EM, Meyerhardt JA, Mamon HJ. Selective versus standard use of neoadjuvant chemoradiation for locally advanced cancers prior to total mesorectal excision: surgical endpoints from the PROSPECT trial/N1048, 2020. e-Pub 2020.
      26. Zafar S, Hu C, Snyder RA, Cuddy A, You YN, Lowenstein LM, Volk RJ, Chang GJ. Predicting Risk of Recurrence after Colorectal Cancer Surgery in the United States: An Analysis of a Special Commission on Cancer National Study, 2019. e-Pub 2019.
      27. Yang Y, Malakorn S, Zafar SN, Sandhu L, Chang GJ. Robotic Complete Mesocolic Excision for Right Colectomy in a High-BMI Patient: "SMV-first" Approach, 2019. e-Pub 2019.
      28. Malakorn S, Bednarski BK, You YN, Chang GJ. Tumor Sidedness, Recurrence and Survival Another Important Difference Between Localized Colon Cancer, 2019. e-Pub 2019.
      29. Healy M, Bednarski BK, Eng C, Das M, Rodriguez-Bigas MA, Skibber JM, Kaur H, Ernst R, Chang GJ, You YN. Higher Propensity for Nodal Metastases Among Young-Onset Rectal Cancers, 2019. e-Pub 2019.
      30. Sandhu L, Romero M, Weldon M, You YN, Bednarski BK, Chang GJ. Is Extended VTE Prophylaxis After Minimally Invasive Surgery for Colorectal Cancer Justified? Results of a Systematic Literature Review, 2018. e-Pub 2018.
      31. Chai CY, Chang GJ, Tran Cao H, Awad SS, Kimbrough BA, Artinyan A, Krishnan B, Massarweh NN. Management of Early Stage Squamous Cell Carcinoma of Anal Canal - Is Doing Less More, 2018. e-Pub 2018.
      32. Sammour T, Malakorm S, Chang GJ, Rodriguez-Bigas MA, Bednarski BK, Eng C, Das P, Skibber JM, You YN. Longitudinal Trajectory of Cancer Survivorship in Patients with Recurrent Rectal Cancer: Anatomy of Recurrence Impacts Quality of Life and Pain, 2017. e-Pub 2017.
      33. Adesoye T, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, You YN, Van Loon K, Schrag D, McKellar DP, Winchester DP, Chang GJ. Impact of Adjuvant Chemotherapy on Recurrence Risk in Stage II Colon Cancer, 2017. e-Pub 2017.
      34. Sammour T, Malakorn S, Thampy R, Kaur H, Bednarski BK, Messick C, Taggart M, Chang GJ, You YN. Minimally Invasive Complete Mesocolic Excision and Central Vascualr Ligation: Defining the Radicality of Central Lymphadenectomy for Right Colon Cancer, 2017. e-Pub 2017.
      35. Sammour T, Malakorm S, Chang GJ, Rodriguez-Bigas MA, Bednarski BK, Eng C, Das P, Skibber JM, You YN. Longitudinal Trajectory of Cancer Survivorship in Patients with Recurrent Rectal Cancer: Anatomy of Recurrence Impacts Quality of Life and Pain, 2017. e-Pub 2017.
      36. Adesoye T, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, You YN, Van Loon K, Schrag D, McKellar DP, Winchester DP, Chang GJ. Impact of Adjuvant Chemotherapy on Recurrence Risk in Stage II Colon Cancer, 2017. e-Pub 2017.
      37. Sammour T, Malakorn S, Thampy R, Kaur H, Bednarski BK, Messick C, Taggart M, Chang GJ, You YN. Minimally Invasive Complete Mesocolic Excision and Central Vascualr Ligation: Defining the Radicality of Central Lymphadenectomy for Right Colon Cancer, 2017. e-Pub 2017.
      38. Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, You YN, Schrag D, McKellar D, Winchester D, Kozower B, Greenberg CC, Chang GJ. Intensity of Post-Treatment Surveillance Does Not Impact Survival in Colorectal Cancer, 2017. e-Pub 2017.
      39. Schumacher JR, Neuman HB, Zhang Y, Yu M, Vanness DJ, Si Y, Burnside ES, Ruddy KJ, Partridge AH, Schrag D, Edge SB, Jacobs EA, Havlena J, Francescatti AB, Winchester DP, McKellar DP, Spears PA, Chang GJ, Kozower BD, Greenberg CC. Asymptomatic distant recurrence detection and survival in early stage breast cancer: A nationally representative study, 2017. e-Pub 2017.
      40. Cuddy A, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Bednarski BK, Messick CA, Nguyen S, You YN. Primary Health Concerns Perceived by Long-Term Disease-Free Colorectal Cancer Survivors, 2016. e-Pub 2016.
      41. Lowenstein LM, Hempstead AP, Richards VF, Van Loon K, You YN, Volk RJ, Chang GJ. Patient Self-Advocacy in Decision Making Related to Post-Treatment Surveillance for Colorectal Cancer, 2016. e-Pub 2016.
      42. Patel SH, Chang GJ, Cuddy A, Mork ME, Bannon SA, Egger ME, Holder A, Bednarski BK, Skibber JM, Vilar-Sanchez E, Lynch PM, Rodriguez-Bigas MA, You YN. Decision for Non-Completion of Follow-Up Among Patients with Abnormal Screening Test for Heredity Colorectal Cancer Syndrome, 2016. e-Pub 2016.
      43. You YN, Chang GJ, Bailey CE, Tran Cao HS, Cuddy A, Bednarski B, Feig BW, Nguyen S, Rodriguez-Bigas MA, Skibber JM. Risks and Distribution of Secondary Cancers Among Long-Term Survivors of Colon and Rectal Cancer, 2016. e-Pub 2016.
      44. Snyder RA, Hu CY, Cuddy A, Francescatti AB, Schumacher JR, You YN, McKellar D, Winchester DP, Chang GJ. Detection and Treatment of Colorectal Cancer (CRC) Recurrence During Routine Surveillance: A Nationwide Cohort Study 34(suppl; abstr e18137), 2016. e-Pub 2016.
      45. Lowenstein LM, Cuddy A, Hempstead AP, Richards V, You YN, Volk RJ, Chang GJ. Patient's Knowledge of Colorectal Cancer Surveillance and Recurrence: A Qualitative Study, 2016. e-Pub 2016.
      46. Van Loon K, Hu CY, Cuddy A, Bekaii-Saab T, Benson AB, Hall MJ, Lai L, Nurkin S, Skibber JM, Weiser MR, Schrag D, Chang GJ. How are Colorectal Cancer Patients Treated Following Cancer Recurrence During Follow-up?, 2016. e-Pub 2016.
      47. Bailey CE, Hu CY, Cuddy A, You YN, Chang GJ. Surveillance Imaging Following Colon Cancer Resection: Universal or Risk-Based?, 2015. e-Pub 2015.
      48. Morris VK, Rashid A, Rodriguez-Bigas MA, Das P, Wolff RA, Chang GJ, Crane CH, Phillips J, Ohinata A, Rogers J, Eng C. Association of human papillomavirus with unique clinicopathologic features in patients with metastatic squamous cell carcinoma of the anal canal 32(suppl 3; abstr 479), 2014. e-Pub 2014.
      49. You YN, Bednarski BK, Chang GJ, Nguyen S, Cuddy A, Feig BW, Skibber JM, Rodriguez-Bigas MA. Defining Phenotypes and Pedigrees in Young onset Colorectal Cancer, 2013. e-Pub 2013.
      50. Kopetz S, Jiang Z, Overman M, Rosenburg R, Salazar R, Tabernero J, Stork L, Li Y, Simon I, Chang GJ, Maru D. Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients J Clin Oncol 31(suppl; abstr 3612), 2013. e-Pub 2013.
      51. Chang GJ, Park IJ, Eng C, You YN, Kopetz S, Overman MJ, Rodriguez-Bigas MA, Skibber JM. Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal Cancer J Clin Oncol 30(suppl; abstr 3556), 2012. e-Pub 2012.
      52. Eng C, Rogers J, Chang GJ, You YN, Das P, Rodriguez-Bigas MA, Ohinata A, Phillips J, Abbruzzese JL, Wolff RA. Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal J Clini Oncol 30(suppl; abstr 4060), 2012. e-Pub 2012.
      53. Park IJ, You NY, Skibber JM, Rodriguez-Bigas MA, Feig BW, Nguyen ST, Chang GJ. Oral Presentation, Recurrence patterns after multidisciplinary therapy for rectal cancer in 725 patients, 2012. e-Pub 2012.
      54. Russell MC, Chiang YJ, Feig BW, Chang GJ, Rodriguez-Bigas MA, Skibber JM, Chagpar R, Cormier JN, You YN. Lymph node metastasis in patients with early pathologic T-stage rectal cancers: What does local excision leave behind?, 2012. e-Pub 2012.
      55. Russell MC, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Feig BW, You YN. Detection of hereditary nonpolyposis colorectal cancer (HNPCC) in non-caucasian patients, 2012. e-Pub 2012.
      56. Abbott DE, Cantor SB, Rodriguez-Bigas MA, Chang GJ, Lynch PM, Feig BW, Skibber JM, You YN. Detecting herediatary nonpolyposis colorectal cancer syndrome (HNPCC) in colorectal cancer (CRC) patients: Optimal strategies at lower costs, 2012. e-Pub 2012.
      57. Haynes A, Chiang YJ, Feig B, Xing Y, Chang GJ, You YN, Cormier J. Association between delays in adjuvant chemotherapy for stage II and III colon cancer and increased mortality, 2012. e-Pub 2012.
      58. Hyngstrom JR, Rodriguez-Bigas MA, Chang GJ, Taggert MW, Skibber JM, Feig BW, You YN. Oral Presentation, Microsatellite high colorectal cancer: Does the underlying mechanism for instability matter?, 2012. e-Pub 2012.
      59. Hyngstrom JR, Rodriguez-Bigas MA, Chang GJ, Taggart MW, Skibber JM, Feig BW, You YN. Microsatellite high colorectal cancer: Does the underlying mechanism for instability matter? J Clin Oncol 30(suppl 4; abstr 575), 2012. e-Pub 2012.
      60. Haynes A, Chiang YJ, Feig B, Xing Y, Chang GJ, You YN, Cormier J. Association between delays in adjuvant chemotherapy for stage II and III colon cancer and increased mortality J Clin Oncol 30(suppl 4; abstr 541), 2012. e-Pub 2012.
      61. Abbott DE, Cantor SB, Rodriguez-Bigas MA, Chang GJ, Lynch PM, Feig BW, Skibber JM, You YN. Detecting hereditary nonpolyposis colorectal cancer syndrome (HNPCC) in colorectal cancer (CRC) patients: Optimal strategies at lower costs J Clin Oncol 30(suppl 4; abstr 396), 2012. e-Pub 2012.
      62. Russell MC, Rodriguez-Bigas MA, Chang GJ, Skibber JM, Feig BW, You YN. Detection of hereditary nonpolyposis colorectal cancer (HNPCC) in non-Caucasian patients J Clin Oncol 30(suppl 4; abstr 417), 2012. e-Pub 2012.
      63. Mitchell MP, Abboud M, Crane C, Eng C, Chang GJ, Rodriguez-Bigas MA, Skibber JM, You YN, Beddar S, Krishnan S, Delclos ME, Das P. Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience J Clin Oncol 30(suppl 4; abstr 661), 2012. e-Pub 2012.
      64. Overman MJ, Fournier KF, Hu CY, Wolff RA, Eng C, Taggart MW, Royal RE, Mansfield PF, Chang GJ. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histologic grade J Clin Oncol 30(suppl 4; abstr 402), 2012. e-Pub 2012.
      65. Boland GM, Chiang Y, Chagpar R, Xing Y, Hu CY, Fieg BW, Chang GJ, You N, Cormier JN. Association of NCCN guideline adherence with improved survival in hihg-risk stage II and III colon cancer J Clin Oncol 30(suppl 4; abstr 543), 2012. e-Pub 2012.
      66. Das P, Eng C, Rodriguez-Bigas, Chang GJ, Skibber JM, Maru D, Munsell MF, Clemons MV, Kopetz S, Garrett CR, Shureiqi I, Krishnan S, Delclos ME, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial J Clin Oncol(suppl 4; abstr 544), 2012. e-Pub 2012.
      67. Tzeng CD, Chang GJ, Curley SA, Vauthey JN, Ellis LM, Skibber JM, Feig BW, Abdalla EK, Aloia TA, You YN, Rodriguez-Bigas MA. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: A matched case-control analysis J Clin Oncol 30(suppl 4; abstr 629), 2012. e-Pub 2012.
      68. Park IJ, Eng C, You YN, Kopetz S, Rodriguez-Bigas MA, Overman MJ, Skibber JM, Chang GJ. Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer J Clin Oncol 30(suppl 4: abstr 557), 2012. e-Pub 2012.
      69. Chang GJ, Hu CY, You YN, Eng C, Rodriguez-Bigas MA, Skibber JM. What determines adjuvant chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer? J Clin Oncol 30(suppl 4; abstr 546), 2012. e-Pub 2012.
      70. Russell MC, Chiang Y, Feig BW, Chang GJ, Rodriguez-Bigas MA, Skibber JM, Chagpar R, Cormier JN, You YN. Lymph node metastasis in patients with early pathologic T-stage rectal cancers: What does local excision leave behind? J Clin Oncol 30(suppl 4; abstr 537), 2012. e-Pub 2012.
      71. Bailey C, Hu C, You N, Rodriguez-Bigas M, Kaur H, Ernst R, Skibber M, Chang GJ. Population-based trends in position emission tomography (PET) utilization after resection for colon cancer J Clin Oncol 30(suppl; abstr 3556), 2012. e-Pub 2012.
      72. Abbott DE, Aloia TA, Rodriguez-Bigas MA, Skibber JM, Feig BW, You NY, Curley SA, Vauthey JN, Chang GJ. Economic comparison of simultaneous and staged resection for synchronous metastatic colorectal cancer, 2011. e-Pub 2011.
      73. Park, IJ, Chang GJ. Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer J Clin Oncol 29(suppl; abstr 3553), 2011. e-Pub 2011.
      74. Chagpar R, Cormier JN, Feig BW, Chang GJ, You YN, Chiang M, Rodriguez-Bigas MA, Skibber JM, Xing Y. Adherence to NCCN treatment guidelines for rectal cancer: Analysis of national practice patterns J Clin Oncol 29(suppl; abstr 3554), 2011. e-Pub 2011.
      75. Chang GJ, Park IJ, You YN, Hu C, Hamilton SR, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Nguyen ST, Rodriguez-Bigas MA, Skibber JM. Neoadjuvant treatment response and outcomes is locally advanced rectal cancer: Establishing oncologic benchmarks J Clin Oncol 29(suppl; abstr 3545), 2011. e-Pub 2011.
      76. Chang GJ, You NY, Kaur H, Ernst RD. Can Pretreatment Rectal MRI Predict Response to Neoadjuvant Chemoradiation Therapy?, 2011. e-Pub 2011.
      77. Chagpar R, Cormier JN, Xing Y, Chiang Y, Chang GJ, You YN, Rodriguez-Bigas MA, Skibber JM, Feig BW. Which stage II colon cancer patients are receiving recommendations for adjuvant chemotherapy? An analysis of current practices using the National Cancer Database, 2011. e-Pub 2011.
      78. Chagpar R, Xing Y, Hsu C, Cormier JN, Rashid A, Chiang Y, Feig BW, Chang GJ, You, YN. Comparison and validation of three staging systems for neuroendocrine tumors of the colon and rectum, 2011. e-Pub 2011.
      79. Jensen C, Ernst R, Chang GJ, You N, Hou P, Choi H, Rauch G, Kaur H. Preoperative MRI assessment of rectal cancer: Historical perspective to current trends, 2011. e-Pub 2011.
      80. Park IJ, You YN, Schlette E, Nguyen S, Rodriguez-Bigas MA, Skibber JM, Chang GJ. The “Reverse” Hybrid Robotic Mesorectal Excision for Rectal Cancer, 2011. e-Pub 2011.
      81. Hyngstrom JR, Hu C, Xing Y, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Cormier JM, Chang GJ. Clinicopathology and Outcomes with Mucinous and Signet Ring Colorectal Adenocarcinoma in the NCDB, 2011. e-Pub 2011.
      82. Hsu C, Rashid A, Xing Y, Chiang Y, Chang GJ, You N, Feig B, Cormier J. Histologic subtypes of neuroendocrine tumors of the appendix have varying malignant potential, 2011. e-Pub 2011.
      83. Chagpar R, Xing Y, You YN, Chiang Y, Feig BW, Chang GJ, Cormier JN. Predicting adherence to stage-specific treatment guidelines for adenocarcinoma of the colon, 2011. e-Pub 2011.
      84. You Y, Xing Y, Feig BW, Rodriguez-Bigas MA, Skibber JM, Chang GJ, Ling YK, Cormier JN. Risk factors for colorectal cancer in patients younger than 50, 2011. e-Pub 2011.
      85. Hu C, Xing Y, Cormier JN, Chang GJ. The validity of cancer specific mortality within the surveillence, epidemiology, and end results registry, 2011. e-Pub 2011.
      86. Jiang Z, Mehta TR, You YN, Chang GJ, Eng C, Overman JM, Maru D, Hamilton SR, Kopetz S. Association of PTEN loss and local recurrence in stage II-III colon cancer J Clin Oncol 29(suppl; abstr 399), 2011. e-Pub 2011.
      87. Eng C, Xing Y, You YN, Chang GJ, Das P, Phillips J, Wolff RA, Rodriguez-Bigas AM, Ohinata A, Crane CH. Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective, 2011. e-Pub 2011.
      88. You YN, Xing Y, Feig BW, Rodriguez-Bigas MA, Skibber JM, Chang GJ, Cormier JN. Advanced-stage colon cancer prior to the screening age: Association with age, race, and insurance status J Clin Oncol 29(suppl; abstr 377), 2011. e-Pub 2011.
      89. Ernst RD, Kaur H, You YN, Chang GJ, Rodriguez-Bigas M. Structured reporting for MRI staging of rectal cancer, 2010. e-Pub 2010.
      90. You Y, Choi EA, Skibber JM, Rodriguez-Bigas MA, Feig BW, Eng C, Crane CH, Das P, Chang GJ. Multimodal salvage therapy for locally recurrent and re-recurrent rectal cancer, 2010. e-Pub 2010.
      91. Chang GJ, Maru D, Agarwal A, Schlette E, Wolff R, Rodriguez-Bigas M, You N, Feig B, Kopetz S, Skibber J, Eng C. Histophathologic responses in primary tumors of patients with metastatic colorectal carcinoma after neoadjuvant systemic chemotherapy alone, 2010. e-Pub 2010.
      92. You YN, Habiba H, Chang GJ, Rodriguez-Bigas MA, Skibber JM. Prognostic value of pain and quality of life in patients with locally recurrent rectal cancer, 2010. e-Pub 2010.
      93. McAuliffe PF, Gershenwald JE, Lee JE, Badgwell BD, Ballo MT, Cormier JN, Mansfield PF, Chang GJ, Zagars GK, Camp ER. Role of sentinel lymph node biopsy in anorectal melanoma, 2010. e-Pub 2010.
      94. Bowles TL, Hu, C, Skibber JM, Rodriguez-Bigas MA, Chang GJ. Cancers of the Colon and Rectum, 2010. e-Pub 2010.
      95. Eng C, Sethi S, Chang GJ, Rodriguez-Bigas MA, Skibber JM, Shen J, Zhu J, Ohinata A, Hamilton SR, Li D. Proteomic analysis of potential tumor markers in AJCC stage II and III colon cancer, 2009. e-Pub 2009.
      96. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal, 2009. e-Pub 2009.
      97. Overman MJ, Hu CY, Wolff RA, Chang GJ. Impact of lymph node evaluation on survival for small bowel adenocaricnoma (SBA): Analysis of the Surveillance, Epidemiology and End Results (SEER) database, 2009. e-Pub 2009.
      98. Hu C, Xing Y, Cormier JN, Chang GJ. The validity of cause of death coding within the surveillance, epidemiology, and end results (SEER) registry, 2009. e-Pub 2009.
      99. Fukami N, Skibber JM, Chang GJ. Salvage endoscopic antegrade dilation on tight or complete coloanal anastomotic stricture via ileostomy, 2009. e-Pub 2009.
      100. Xing Y, Chang GJ, Hu C, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates provide better prognostic information for melanoma survivors: result from the SEER dataset 1988-2000, 2009. e-Pub 2009.
      101. Bedrosian I, Hu CY, Chang GJ. Contralateral prophylactic mastectomy and survival, 2008. e-Pub 2008.
      102. Chang GJ, Hu C, Rodriguez-Bigas MA, Skibber JM. Improving colon cancer prognosis using index of metastasis: A SEER analysis, 2008. e-Pub 2008.
      103. Chang GJ, Taylor SH, Rodriguez-Bigas MA, Eng C, Skibber JM. The twelve lymph node standard in colon cancer: Can it be achieved?, 2008. e-Pub 2008.
      104. Bowles TL, Xing Y, Mungovan KS, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JN. Conditional survival estimates improve over 5 years for patients with node-positive melanoma, 2008. e-Pub 2008.
      105. Chang GJ, Taylor SH, Rodriguez-Bigas MA, Eng C, Skibber JM. The twelve lymph node standard in colon cancer: Can it be achieved?, 2008. e-Pub 2008.
      106. Chang GJ, Hu C, Eng C, Skibber JM, Rodriguez-Bigas MA. An epidemiologic study of conditional survival in colon cancer, 2008. e-Pub 2008.
      107. Chang GJ, Hu C, Rodriguez-Bigas MA, Eng C, Skibber JM. Improving colon cancer prognosis using index of metastasis: A SEER analysis, 2008. e-Pub 2008.
      108. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Ebdalla EK, Kopetz ES, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not increase postoperative complications in patients undergoing hepatic surgery for colorectal cancer liver metastases, 2007. e-Pub 2007.
      109. Choi EA, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ. Predicting outcomes after surgery for locally recurrent rectal cancer, 2007. e-Pub 2007.
      110. Chang GJ, Rodriguez-Bigas MA, Skibber JM. An epidemiologic study of N-stage after preoperative radiotherapy for rectal cancer, 2007. e-Pub 2007.
      111. Badgwell B, Feig BW, Ross M, Mansfield PM, Chang GJ. Pneumoperitoneum in the cancer patient, 2007. e-Pub 2007.
      112. Gray KD, Feng L, Skibber JM, Chang GJ, Rodriguez-Bigas MA. Ethnic disparities in colorectal cancer outcomes persist despite treatment at a comprehensive cancer center, 2007. e-Pub 2007.
      113. Al-Refaie WB, Pisters PW, Chang GJ. Gastric adenocarcinoma in young patients: A population-based appraisal, 2007. e-Pub 2007.
      114. Das P, Bhatia S, Eng C, Ajani, JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Krishnan S, Crane CH. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer, 2007. e-Pub 2007.
      115. Bedi M, Das P, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Eng C, Wolff RA, Krishnan S, Janjan N, Crane CH. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer, 2007. e-Pub 2007.
      116. Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. An epidemiologic study of N-stage and prognosis after preoperative radiotherapy for rectal cancer, 2007. e-Pub 2007.
      117. Lim SJ, Feig BW, Hunt KK, Rodriguez-Bigas MA, Skibber JM, Cleary K, Chang GJ. Evaluation of sentinel lymph node for staging accuracy in colon cancer, 2007. e-Pub 2007.
      118. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey N, Rodriguez-Bigas MA, Curley SA, Feig BW. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab (BC) for colorectal cancer (CRC) liver metastases, 2007. e-Pub 2007.
      119. Choi EA, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ. Surgical salvage with bone resection for locally recurrent rectal cancer, 2007. e-Pub 2007.
      120. Al-Refaie WB, Pisters PW, Chang GJ. Proximal versus total gastrectomy for proximal gastric cancer, 2007. e-Pub 2007.
      121. Choi EA, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ. Composite sacral resection for recurrent rectal cancer, 2007. e-Pub 2007.
      122. Zager JS, Gannon CJ, Chang GJ, Feig BW, Skibber J, Rodriguez-Bigas MA. Pelvic exenteration affords safe and durable treatment for locally advanced rectal adenocarcinoma (LARC), 2006. e-Pub 2006.
      123. Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas MA. Extending the limits for sphincter preservation for rectal cancer with margins less than or equal to 1cm, 2006. e-Pub 2006.
      124. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Ra W, Eng C, Janjan NA, Krishnan S, Crane CH. Predictors of tumor responlse and downstaging in patients treated with preoperative chemoradiation for rectal cancer 66 (Suppl):S167-68, 2006. e-Pub 2006.
      125. Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas MA. Are we under-treating rectal cancer in elderly patients? A population based appraisal, 2006. e-Pub 2006.
      126. Choi E, Rodriguez-Bigas MA, Skibber JM, Chang GJ. Predicting outcome after aggresive surgical resection of locally recurrent rectal cancer, 2006. e-Pub 2006.
      127. Chang GJ, Kattepogu KM, Wey J, Gannon C, Crane CH, Janjan N, Feig BW, Skibber JM, Rodriguez-Bigas MA. sphincter preservation in distal rectal cancer beyond the 2 cm rule, 2006. e-Pub 2006.
      128. Das P, Bhatia Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Delclos ME, Krishnan S, Ellis LM, Lin EH, Janjan N, Crane C. Neoadjuvant chemoradiation with capecitabine versus infusional 5-fluorouracil (5-FU) for locally advanced rectal cancer: a matched case-control study, 2005. e-Pub 2005.
      129. Chang GJ, Liu T, Feng S, Bedolli M, O’Rourke RW, Schmidt G, Roberts JP, Stock PG. Targeted gene therapy with CD40Ig to induce long-term acceptance of liver allografts, 2002. e-Pub 2002.
      130. Chang GJ, Adey D, Tomlanovich S, Amend W, Vincenti F. Early Histology, Acute Rejection, and Outcome in Renal Transplant Patients with Severe Delayed Graft Function Treated with a Calcineurin Inhibitor-Free Regimen 12:882A, 2001. e-Pub 2001.
      131. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high grade anal squamous intraepithelial lesions—a prospective study, 2001. e-Pub 2001.
      132. Chang GJ, Freise CE, Hirose R, Ascher NL, Roberts JP, Vincenti F, Stock PG. A new immunosuppressive era—transplantation without steroids, 2000. e-Pub 2000.
      133. Chang GJ, Vincenti F, Robert JP, Stock PG, Hirose R. Sirolimus provides effective immunosupression in kidney transplant recipients with delayed or impaired graft function, 2000. e-Pub 2000.
      134. Chang GJ, Mahanty HD, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R. Experience with the use of Sirolimus in Liver Transplantation—Use in patients for whom calcineurin inhibitors are contraindicated 32/(4:2/2):344A, 2000. e-Pub 2000.
      135. Chang GJ, Ascher NL, Freise CE, Jaskula J, Mathias R, Portale A, Potter DE, Stock PG. Daclizumab provides superior immunosuppresion for pediatric renal transplants 67(9):S585, 1999. e-Pub 1999.
      136. Chang GJ, O’Rourke R, Lee I, Stock PG, Vincenti F. One or Two Doses of Dacluzimab Provide Effective Immunosuppression for Renal Transplant Patients with High Immunologic Risk or with Delayed Graft Function 67(7):S149, 1999. e-Pub 1999.
      137. Berber E, Engle KL, Chang GJ, Macho J, Pear JM. Selective use of tube cholecystostomy with interval laparoscopic cholecystectomy in acute cholecystitis, 1998. e-Pub 1998.
      138. Chang GJ, Honda HM, Ignarro LJ, Demer LL. Nitrix oxide oxides low density lipoprotein in a pH-dependent manner, 1993. e-Pub 1993.
      139. Moskowitz JB, Mork ME, Maghanoy E, Nguyen ST, Harrison DM, Lovero KR, Das P, Chang GJ, Thirumurthi S, Ricciardiello L, Sanchez EV, You Y. Empowering young-onset colorectal cancer patients with an accessible, self-navigable online platform for universal germline testing. 2025 ASCO Annual Meeting.
      140. Basch E, Dueck AC, Mitchel SA, Mamon HJ, Rogak LJ, Ginos BF, Weiser MR, Saltz LB, Chang GJ, Minasian LM, Denicoff AM, Thanarajasingam G, Rubinson DA, Gordon VL, Goerge TJ, Farma JM, O'Reilly EM, Meyerhardt JA, Shi Q, Scrag D. PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048). 2023 ASCO Annual Meeting.
      141. Bhutiani N, Johnson B, Kopetz S, White M, Willis J, Uppal A, Chang GJ. Immune Checkpoint Blockade Combined with Targeted Therapies Provide Increased Disease Control in Mismatch Repair-Proficient Colorectal Cancer with Peritoneal Metastases. ASCO Gastrointestinal Cancers Symposium.
      142. Chang GJ, Childers CP, Hu CY. Impact of 2021 & 2023 Evaluation & Management (E&M) Code Updates on Surgical Oncologists. SSO 2024 Annual Meeting.
      143. Konishi T, Uppal A, White M, Messick C, You YN, Skibber J, Bednarski BK, Chang GJ. Robotic Nerve-Preserving Lateral Lymph Node Dissection with Major Vessel Ligation - When and How We Do It?. 2024 American Society of Colon and Rectal Surgeons.
      144. Ochiai K, Stanietzky N, Surabhi V, Ikeda A, Uppal A, White MG, Peacock O, Messick CA, Bednarski BK, You YN, Skibber JM, Kaur H, Chang GJ, Konishi T. Splenic enlargement after neoadjuvant chemotherapy predicts postoperative complications after curative proctectomy for rectal cancer. 2024 American Society of Colon and Rectal Surgeons.
      145. Diggs LP, Galbraith NJ, Ramamurthy J, Bhutiani N, Hu ZI, Dasari A, Overman MJ, Kopetz S, Chang GJ, Bednarski BK, Trueba MG, Behman RS, Yin F, Ajami NJ, Wargo JA, Bullman S, Johnston CD, You Y, White M. A phase II trial utilizing metronidazole to optimize the microbiome of rectal adenocarcinoma undergoing neoadjuvant therapy. 2025 ASCO Annual Meeting.
      146. Ochiai K, Bhutiani N, Uppal A, You Y, Bednarski BK, White M, Holliday E, Das P, Chang GJ, Konishi T. Long-course chemoradiation vs short-course radiation in total neoadjuvant therapy for rectal cancer: propensity score case-matched analysis. 2025 ASCO Gastrointestinal Cancers Symposium.
      147. Miyakawa T, Lie JJ, Hu C, Ochiai K, Behman RS, Guraieb-Trueba M, Bednarski BK, Konishi T, Messick C, You Y, Holliday E, Noticewala SS, Das P, Kaur H, Rauch GM, Huey RW, Dasari A, Chang GJ. Survival outcomes in rectal cancer with ypTNM vs pTNM staging after neoadjuvant therapy. 2025 ASCO Annual Meeting.
      148. Shi Q, Chang GJ, Pederson LD, Asare EA, Jin Z, Cohen R, Meyerhardt JA, Andre T, Tie J, Dixon JG, Palis BE, Ballman KV, Yothers G, Ma Z, Alberts SR, Shi C, Washington MK, Taieb J, Steele S, Goldberg RM. Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP). 2025 ASCO Annual Meeting.

      Book Chapters

      1. Bednarski, BK, Chang, GJ. Exenterative Resections Involving Vascular and Pelvic Sidewall Structures, 110-119, 2021.
      2. Malakorn, S, Sammour, T, Chang, GJ. Robotic pelvic exenteration, 259-273, 2019.
      3. Chang GJ, Ninan T. Colorectal Cancer Survivorship Care. In: Handbook of Cancer Survivorship Care. Springer, 2018.
      4. Loehrer AP, Chang GJ. Implications of the Affordable Care Act on Surgery and Cancer Care. In: Surg Oncol Clin N Am. 4, 603-614, 2018.
      5. Karanjawala, BE, Chang, GJ. Management of anal cancer, 555-566, 2015.
      6. Karanjawala BE, Chang GJ. Management of Anal Cancer. In: Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances. Springer, 555-66, 2015.
      7. Bailey CE, Chang GJ. Clinical Trials: Handling the Data. In: Success in Academic Surgery: Clinical Trials. 2014. Springer, 2014.
      8. Park IJ, Chang GJ. Salvage Surgery for Recurrent/Persistent Anal Cancer". In: Anal Cancer, A Multidisciplinary Approach. Demos Medical, 2013.
      9. Pineda, CE, Chang, GJ, Welton, ML. Surgery in the Immunocompromised Patient, 2262-2272, 2012.
      10. Chang GJ. Surgical Mentoring: Building Tomorrow's Leaders. In: Diseases of the Colon & Rectum. Springer, 2012.
      11. Chang GJ, Shelton A, Welton ML. Large Instestine. In: Current Surgical Therapy. Appleton, 2009.
      12. Welton, ML, Shelton, A, Chang, GJ, Varma, MG. Colon, rectum, and anus, 1011-1110, 2008.
      13. Welton ML, Shelton A, Chang GJ, Varma M. Colon, Rectum, and Anus. In: Surgery: Basic Science and Clinical Evidence. Springer-Verlag, 2008.
      14. Chang GJ. Open and Laparoscopic Surgery for Colon Cancer. In: Advanced Therapy in Surgical Oncology. Decker Press, 2007.
      15. Shelton A, Chang GJ, Welton ML. Small Intestine. In: Current Surgical Diagnosis and Treatment. Appleton Lange, 2006.
      16. Chang GJ, Feig BW. Cancer of the Colon, Rectum, and Anus. In: The M.D. Anderson Surgical Oncology Handbook. W.B. Saunders. Lippincott Williams & Wilkins, 2006.
      17. Chang GJ, Shelton A, Welton ML. Large Intestine. In: Current Surgical Diagnosis and Treatment. Appleton Lange, 2006.
      18. Chang GJ, Welton ML. Surgery in the Immunocompromised Patient. In: Shackelford’s Surgery of the Alimentary Tract. W.B. Saunders, 2005.
      19. Welton ML, Chang GJ. Anorectum. In: Current Surgical Diagnosis and Treatment. Appleton Lange, 2005.
      20. Chang GJ, Shelton A, Schrock TR, Welton ML. Large Intestine. In: Current Surgical Diagnosis and Treatment. Appleton Lange, 2002.
      21. Chang GJ, Welton ML. Surgery in the Immunocompromised Patient. In: Shackelford’s Surgery of the Alimentary Tract. W.B. Saunders, 2002.
      22. Chang GJ, Welton ML. Other Abdominal Emergencies: Appendicitis, Diverticulitis, and Ischemic Bowel. In: Hospital Medicine. Lippincott Williams & Wilkins, 683-694, 2000.
      23. Massarweh N, Chang GJ. Comparative Effectiveness Research. In: Success in Academic Surgery: Health Services Research.
      24. deRosa N, Chang GJ. Locally advanced and recurrent rectal cancer. In: Scientific American Surgery.

      Books (edited and written)

      1. Hunt, KK, Katz, MH, Veeramachaneni, N, Grubbs, EG, Wang, TS, Kanf, JM, Fields, RC, Maithee, SK, Chang, GJ, Halverson, AL, Reddy, RM, Martin, LW, Francfsatti, AB. Operative standards for cancer surgery, 2018.
      2. Hunt, KK, Katz, MH, Veeramachaneni, N, Grubbs, EG, Wang, TS, Kanf, JM, Fields, RC, Maithee, SK, Chang, GJ, Halverson, AL, Reddy, RM, Martin, LW, Francfsatti, AB. Operative standards for cancer surgery, 2018.
      3. Chang, GJ. Rectal cancer, 2018.
      4. Chang GJ. Rectal Cancer: Modern Approaches to Treatment. Springer Nature, 2018.
      5. Chang GJ. Operative Standards for Cancer Surgery, 2018.
      6. Chang GJ. Operative Standards for Cancer Surgery. Lippincott Williams & Wilkins, 2015.

      Letters to the Editor

      1. Massarweh NN, Hu CY, Rodriguez-Bigas MA, Chang GJ. Reply to N.H. Turner et al and L. Dziki et al. J Clin Oncol 33: 1412, 2015.
      2. Maru DM, Agarwal AA, Hu CY, Chang GJ. Reply to Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation followed by surgery?. Cancer 120: 1282, 2014.
      Read More
      Less

      Patient Reviews


      CV information above last modified October 22, 2026

      chang
      chang
      chang
      chang

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Colorectal Cancer

      • Colorectal Center

      • Department of Surgical Oncology

      • Division of Surgery

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top